Product Name | Bortezomib |
Description |
Proteasome inhibitor |
Purity | >98% |
CAS No. | 179324-69-7 |
Molecular Formula | C19H25BN4O4 |
Molecular Weight | 384.2 |
Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Storage Temperature | -20ºC |
Shipping Temperature | Shipped Ambient |
Product Type | Inhibitor |
Solubility | Soluble in 50 mg/ml DMSO, 35 mg/ml Ethanol |
Source | Synthetic |
Appearance | White Powder |
SMILES | B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O |
InChI | InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1 |
InChIKey | GXJABQQUPOEUTA-RDJZCZTQSA-N |
Safety Phrases |
Classification: Caution: Substance not yet fully tested. Safety Phrases: S22 - Do not breathe dust S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection S24/25- Avoid contact with skin and eyes |
Cite This Product | Bortezomib (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-328) |
Alternative Names | B-[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid; [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid; Velcade; Radiciol; NSC 681239; DPBA; LDP 341; MG 341; mlN 341; NSC 681239; PS 314; PS 341; Radiciol; Velcade |
Research Areas | Apoptosis, Cancer, Cancer Growth Inhibitors, Proteasome Inhibitors |
PubChem ID | 387447 |
Scientific Background | Potent and selective proteasome inhibitor (Ki=0.6 nM). Inhibits proliferation of a number of tumor cell lines (IC50=7 nM). Inhibits TNF synthesis and FGF-induced angiogenesis. Reversible. Cell permeable. |
References |
1. Adams J., et al. (1999) Cancer Res. 59: 2615. 2. Williams S., et al. (2003) Mol. Cancer Ther. 2: 835. |
StressMarq Biosciences :
Based on validation through cited publications.